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RIP4 inhibits STAT3 signaling to sustain lung
adenocarcinoma differentiation
Jawahar Kopparam1, Johanna Chiffelle1, Paolo Angelino2, Alessandra Piersigilli3,4, Nadine Zangger1,2, Mauro Delorenzi2,5,6 and
Etienne Meylan*,1
Loss of epithelial differentiation and extracellular matrix (ECM) remodeling are known to facilitate cancer progression and are
associated with poor prognosis in patients with lung cancer. We have identified Receptor-interacting serine/threonine protein
kinase 4 (RIP4) as a regulator of tumor differentiation in lung adenocarcinoma (AC). Bioinformatics analyses of human lung AC
samples showed that poorly differentiated tumors express low levels of RIP4, whereas high levels are associated with better overall
survival. In vitro, lung tumor cells expressing reduced RIP4 levels showed enhanced activation of STAT3 signaling and had a
greater ability to invade through collagen. In contrast, overexpression of RIP4 inhibited STAT3 activation, which abrogated
interleukin-6-dependent induction of lysyl oxidase, a collagen cross-linking enzyme. In an autochthonous mouse model of lung AC
initiated by Kras(G12D) expression with loss of p53, Rip4 knockdown tumors progressed to a poorly differentiated state marked by
an increase in Hmga2, reduced Ttf1, and enrichment of genes regulating extracellular remodeling and Jak-Stat signaling. Tail vein
injections of cells overexpressing Rip4 showed a reduced potential to invade and form tumors, which was restored by
co-expression of Stat3. Altogether, our work has identified that loss of RIP4 enhances STAT3 signaling in lung cancer cells,
promoting the expression of ECM remodeling genes and cancer dedifferentiation.
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Dedifferentiation of adenocarcinoma (AC) has been linked to
various features of cancer development such as invasion,
metastasis and stemness of cancer cells.1,2 Mechanisms
involved in dedifferentiation of lung tumors, the leading cause
of cancer-related death,3 are poorly understood. Nuclear
factor-kappa B (NF-κB) and Signal transducer and activator of
transcription 3 (STAT3) are two transcription factors often
activated in lung AC,4–6 and promote dedifferentiation.7,8
Tissue inhibitor of metalloproteinases 1 (TIMP1), a NF-κB
target gene coding for an enzyme involved in extracellular
matrix (ECM) catabolism, was shown to promote cellular
proliferation in lung AC and is associated with a poor
prognosis in patients.9 Interleukin-6 (IL6), a target of NF-κB
and a major activator of STAT3 signaling, promotes pleural
effusion and metastasis of lung cancer.10,11 Recent studies in
lung AC with mutant oncogenic Kirsten rat sarcoma virus
(KRAS), found in 30% of the human disease,12 have shown
that Stat3 acts as a tumor suppressor during cancer initiation
but promotes cancer progression and metastasis in estab-
lished tumors in an Il6-dependent manner.13–15 In multiple
tumor types, STAT3 is known to regulate ECM remodeling
enzymes such as matrix metalloproteinases and collagen
deposition.16–18 These studies suggest that STAT3 signaling is
activated in different steps of tumor progression including
dedifferentiation and metastasis.
Receptor-interacting serine/threonine protein kinases (RIP)
are known to impact cell fate decisions by regulating NF-κB
and Tumor necrosis factor (TNF) signaling amongst
others.19,20 Upon TNF stimulation, RIP1 mediates NF-κB
activation, in the absence of which cells undergo apoptosis.21
RIP3mediated phosphorylation of RIP1 was shown to activate
a pronecrotic complex downstream of TNF stimulation.22
Upon bacterial infection, RIP2 was shown to activate NF-κB in
a Nucleotide-binding oligomerization domain-dependent
manner.23 Recent in vitro studies have hinted towards a role
for RIP members in cancer invasion and metastasis. Indeed,
treatment of lung cancer cells with TNF-related apoptosis-
inducing ligand led to RIP1-mediated STAT3 activation
resulting in increased cell invasion;24 RIP2-mediated activa-
tion of NF-κB was crucial for triple-negative breast cancer cell
motility and invasion.25
RIP4, an ankyrin repeat-containing kinase, promotes
keratinocyte differentiation and inhibits cell migration during
wound healing.26 Rip4 knockout mice are characterized by
poorly differentiated and dysplastic epidermis.27 In humans,
mutations inRIP4 have been linked to an autosomal-recessive
disorder called Bartsocas-Papas syndrome, which is char-
acterized by loss of epidermal differentiation.28,29 In cancer,
RIP4 has been found to have conflicting roles: in diffuse large
B-cell lymphoma (DLBCL) RIP4 promotes cancer progression
by activating the NF-κB pathway and protects the cancer cells
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from chemotherapy-mediated cell death.30 In contrast, retro-
viral insertional mutagenesis in hepatocytes identified RIP4 as
a tumor suppressor in hepatocellular carcinoma.31 These
studies suggest that RIP4 has a context specific function in
cancer progression and in regulating cellular differentiation.
To investigate the role of RIP4 in lung AC progression, we
employed an inducible autochthonous mouse model where
tumors are initiated upon conditional expression of oncogenic
KrasG12D and loss of tumor suppressor p53 (referred to as
KP mice from here on).32 This model develops lung AC that
recapitulates many aspects of the human disease. A previous
study reported that Il6 signaling was activated in this model in
advanced lung AC.33 In our study, we show that RIP4 inhibits
STAT3 signaling and lung cancer dedifferentiation.
Results
Rip4 sustains lung AC differentiation. As a first approach,
we investigated the expression of RIP4 in a compiled publicly
available data set of human lung AC samples. RIP4 mRNA
levels were significantly higher in well-differentiated tumors
compared to medium or poorly differentiated tumors
(Figure 1a). Interestingly, higher RIP4 expression is asso-
ciated with better overall survival (Figure 1b) and, from The
Cancer Genome Atlas (TCGA) data set, with TP53 but not
KRAS mutation status (Supplementary Figures S1a and b).
We then analyzed the effect of Rip4 on tumor progression in
an autochthonous lung AC model. Tumors were initiated by
expression of KrasG12D from its endogenous locus, with loss
of p53 (KP) and expression of a stable shRNA in lung tumor
cells throughout tumor development (Figure 1c). Haematox-
ylin & Eosin (H&E) staining of control tumors eighteen weeks
later showed well-differentiated papillary and glandular
structures. In marked contrast, tumors with Rip4 knockdown
had an increased frequency of undifferentiated patterns
accompanied by multinucleated giant neoplastic cells
(Figure 1d). Analysis of Rip4 mRNA levels by real-time
PCR confirmed sustained Rip4 knockdown in tumors with
shRip4 (Figure 1e). Tumor volumes, as measured by micro-
computed tomography (μCT) prior sacrifice, were not different
upon Rip4 knockdown (Supplementary Figure S1c). Immu-
nohistochemistry (IHC) staining for phospho-histone H3
(pHH3) and cleaved caspase 3 (CC3) revealed no difference
in proliferation or apoptosis (Supplementary Figure S1d). To
confirm the observed altered differentiation at the molecular
level, we analyzed the levels of Ttf1 and Hmga2 by IHC and
real-time PCR. Ttf1 is a marker of well-differentiated lung AC,
which is reduced upon dedifferentiation and metastasis.34 In
contrast, Hmga2 is highly expressed in poorly differentiated
and aggressive lung AC.35 In tumors with Rip4 knockdown,
there was a higher Hmga2 and a reduced Ttf1 expression,
confirming the loss of differentiation of these tumors
(Figures 1d and e,Supplementary Figure S1e). As Rip4 is
known to alter the NF-κB pathway, we investigated NF-κB
activity. IHC revealed no noticeable difference in nuclear
staining of the NF-κB p65 subunit in Rip4 knockdown
compared to control tumors (Supplementary Figure S1d). In
addition, knockdown of RIP4 using siRNA in the human
NCI-H2009 lung AC cell line showed no difference in nuclear
p65, p100 or p52 levels (Supplementary Figure S1f). Hence,
Rip4 knockdown leads to lung tumor dedifferentiation without
affecting NF-κB.
RIP4 inhibits STAT3 activation. Gene expression profiling
followed by gene set enrichment analysis (GSEA) of tumors
with Rip4 knockdown highlighted activation of Jak-Stat
signaling but no difference in NF-κB (Figure 2a). IHC and
immunofluorescence (IF) analysis of tumor sections with Rip4
knockdown showed increased phospho-serine 727 Stat3
(pSerStat3) and nuclear Stat3 levels (Figures 2b and c,
Supplementary Figure S2a) but no difference in phospho-
tyrosine 705 Stat3 (pTyrStat3) (Supplementary Figure S2a).
These results prompted further investigation into a functional
link between RIP4 and STAT3. To trigger STAT3 activation,
we stimulated cells with the cytokine IL6 in some experi-
ments, because it is a potent activator of this pathway.
Altering RIP4 levels by shRNA or by overexpression of WT
RIP4 or kinase-dead RIP4 (RIP4KD) did not affect prolifera-
tion of H2009 cells in vitro (Supplementary Figure S2b).
However, shRNA-mediated RIP4 knockdown resulted in
enhanced pSerSTAT3, but not pTyrSTAT3, in response to
IL6 (Supplementary Figure S2c), and to an increased basal
and IL6-stimulated nuclear STAT3 levels (Supplementary
Figure S2d). To confirm that the altered nuclear STAT3
level is transcriptionally relevant, we monitored the levels of a
bonafide STAT3 target, SOCS3. RIP4 knockdown resulted in
increased IL6-stimulated SOCS3 expression (Supplementary
Figures S2e and f). To confirm the effect of RIP4 on STAT3
signaling, we generated RIP4 knockout (RIP4-KO) H2009
cells using CRISPR/Cas9 gene editing (Supplementary
Figure S2g). RIP4 deletion resulted in faster nuclear import
of STAT3 upon IL6 treatment (Figures 2d and e). Also, these
cells had increased and sustained pSerSTAT3 as well as a
minimally increased nuclear pTyrSTAT3 (Figures 2d and e).
Furthermore, overexpression of RIP4 or RIP4KD reduced
nuclear STAT3 even in the absence of stimulation
(Supplementary Figures S2h and i). These results highlight
an inhibitory role for RIP4 in STAT3 signaling. Interestingly,
overexpression of STAT3 resulting in increased nuclear
STAT3 was sufficient to recruit RIP4 to the nucleus suggest-
ing the presence of an inhibitory feedback loop
(Supplementary Figure S3a). To investigate if RIP4 alters
STAT3 nuclear export, we treated RIP4 overexpressing
H2009 cells with the nuclear export inhibitor leptomycin B
and monitored nuclear STAT3 thereafter, by western blot or
by quantification from IF microscopy. Leptomycin B treatment
rescued RIP4-mediated reduction of nuclear STAT3 suggest-
ing that RIP4 promotes its nuclear export (Supplementary
Figures S3b–d). However, since RIP4 deletion results in
faster nuclear import of STAT3 upon IL6 stimulation
(Figures 2d and e), the inhibitory effect of RIP4 on IL6
signaling is probably not restricted to STAT3 nuclear export.
Finally, although RIP4 is known to activate NF-κB signaling,
reducing NEMO did not alter the impact of RIP4 on
IL6-mediated STAT3 nuclear localization (Supplementary
Figure S3e). Altogether, these results demonstrate that
RIP4 inhibits STAT3 signaling, partly by promoting its
nuclear exit.
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Figure 1 Rip4 regulates lung AC differentiation. (a) RIP4mRNA levels in human lung AC samples were plotted against grade of differentiation. (b) Overall survival of patients
with lung AC, divided into two groups based on median RIP4 expression (high and low), is represented as a Kaplan–Meier plot. Number of patients who have a follow-up for each
year and group has been indicated at the bottom. Cox proportional hazards regression model, P= 0.01, HR= 0.729. (c) Schematic of the mouse model of lung AC is shown.
KrasLSLG12D/WT; p53fl/flmice were intra-tracheally infected with lentivirus carrying cre recombinase and shRNA of interest (Rip4 or control). (d) Tumors were examined 18.5 weeks
after tumor initiation. Representative images of paraffin-embedded lung tumor sections with control shRNA (left) or Rip4 shRNA (right) were stained with H&E, Ttf1 and Hmga2.
Scale bars represent 20 μm. (e) Real-time PCR was performed on cDNA generated from tumor mRNA using probes for Rip4, Ttf1 or Hmga2. Data show mean± S.D. (n= 8)
Mann–Whitney test was used. *Po0.05, **Po0.01. AC, adenocarcinoma; HR, hazard ratio; RMA, robust multi-array average
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RIP4 regulates expression of LOX. Microarray analysis of
tumors with shRip4 uncovered the up-regulation of ECM
receptor interaction genes (Figure 3a). Lysyl oxidase (Lox),
an enzyme involved in collagen crosslinking, has been linked
to the formation of pre-metastatic niches at distant organs.36
Importantly, increased Lox expression was seen in tumors
with shRip4 (Figure 3b). Extended (both 48 and 72 h)
treatment of H2009 with the STAT3 activator IL6 elevated
the levels of LOX, which was completely abolished upon
overexpression of RIP4 or RIP4KD (Figure 3c). Probably
because exposure of H2009 to IL6 reduces the levels of
RIP4, no difference was detected in the amount of LOX
induction in cells with shRIP4 (Supplementary Figures S4a
and b). As collagen is the substrate of LOX, we monitored
collagen deposition using picrosirius red staining of tumor
sections, and quantified the signals under polarized light.
This showed a significant increase in the amount of collagen
in tumors with shRip4 (Figures 3d and e). Finally, we
analyzed human lung AC samples for LOX expression, and
determined that LOX alone was not a prognostic factor of
survival (Supplementary Figure S4c). However, when con-
sidered together, high RIP4 and low LOX levels in tumors
were associated with good prognosis (Figure 3f). These
results show that RIP4 inhibiting STAT3 prevents induction of
LOX, an enzyme involved in ECM remodeling that con-
tributes, with RIP4, to the prognosis of patients with lung AC.
RIP4 reduces the invasiveness of lung cancer cells. Next
we investigated the role of RIP4 on cancer cell invasion both
in vitro and in vivo using matrigel invasion assays and tail vein
injections, respectively. Treating cells with IL6 for 24 h or
knocking down RIP4 alone had no effect on cell invasiveness
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Figure 2 RIP4 inhibits IL6 signaling. (a) Heat map of Jak-Stat signaling genes differentially expressed in tumors with Rip4 knockdown compared to controls.
(b) Representative IHC (top) and IF (bottom) images of paraffin-embedded lung tumor sections stained with Stat3. For IF red (Hoechst) shows nuclei, green Stat3. Scale bars
represent 20 μm. (c) Quantification of the nuclear intensity of Stat3 from IF images of (b). (d) Control and RIP4 knockout (RIP4-KO) H2009 cells were treated with IL6 for different
time intervals (shown in minutes). Nuclear (Nuc)–cytoplasmic (Cyto) proteins were extracted and blotted. PARP and β-tubulin were examined as nuclear and cytoplasmic controls,
respectively. (e) Intensity of STAT3, pTyr-STAT3 and pSer-STAT3 shown in (d) was quantified using ImageJ and normalized to that of PARP or β-tubulin
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(Figure 4a). However, IL6 stimulation in RIP4 knockdown
cells led to a drastic increase in invasion, suggesting that
enhanced activation of STAT3 enabled by RIP4 knockdown is
necessary to promote invasiveness (Figure 4a). Moreover,
overexpression of RIP4 or RIP4KD reduced the invasiveness
of the cells through collagen (Figure 4b, Supplementary
Figure S5a). Treatment of H2009 cells with a LOX inhibitor
(BAPN) attenuated the invasiveness mediated by IL6
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stimulation+RIP4 knockdown (Figure 4c). Next, we devel-
oped a cell line, M8, from a KP mouse tumor, and stably
expressed RIP4 (WT or KD) or a control vector. Confirming
our results obtained in human cells, overexpression of RIP4
or RIP4KD reduced the in vitro invasiveness of M8 cells
through collagen (Supplementary Figures S5b and c), without
interfering with their growth (Supplementary Figure S5d).
Importantly, tail vein injections revealed a significant reduc-
tion in the number of tumors developing in the lungs of mice
injected with either RIP4 or RIP4KD-overexpressing cells
compared to control cells (Figures 4d and e). This suggests
that RIP4 reduces the invasive potential of the cancer cells, a
crucial step for metastasis. Interestingly, 4 of the 6 tumors
extracted from mice injected with RIP4 or RIP4KD-
expressing cells had lost RIP4 expression (Supplementary
Figure S5e), further supporting the notion that RIP4 reduces
the metastatic potential of these cells. To confirm that the
effect of RIP4 on invasiveness of lung cancer cells is due to
its inhibitory effect on STAT3, we developed M8 cells that can
overexpress RIP4 and/or Stat3. Overexpressed Stat3 partly
localized to the nucleus in control and RIP4 overexpressing
conditions (Supplementary Figure S5f). Here again, there
was a reduced number of tumors formed in the lungs after
injection of RIP4 overexpressing cells compared to control.
More importantly, co-expression of Stat3 in these cells
restored the number of lung tumors to that seen in control
conditions (Figures 4f and g), revealing how the inhibitory
action of RIP4 on STAT3 signaling impacts tumor cell
invasiveness. Altogether, our results show that enhanced
STAT3 activity achieved upon RIP4 down-regulation pro-
motes the expression of ECM remodeling genes such as
LOX, which contributes to cancer cell de-differentiation and
metastasis (Figure 5).
Discussion
Activation of STAT3 signaling has been implicated in the
progression of multiple cancers,37,38 and is known to
contribute to oncogenic Kras-driven tumorigenesis.38,39
Tumor cell-specific expression of mutant gp130 (membrane
bound gp130Y757F receptor which mediates Il6 signaling that
can not be suppressed by Socs3) in a Kras mutant-driven
mouse model of lung cancer resulted in increased tumor
burden, which was reverted by the abrogation of hyper-
activated Stat3 through either deletion of Il6 or heterozygous
deletion of Stat3.10 In this study, the contribution of Stat3
signaling was assessed up to 6 weeks after tumor initiation
when the majority of lesions are atypical adenomatous
hyperplasia or early ACs. However, the contribution of Stat3
signaling in late-stage Kras-mutant lung AC, frequently the
stage at which most human patients are diagnosed, is still
unclear.
STAT3 can be activated in different cell types and in
response to multiple stimuli that include cytokines and growth
factors. Therefore, the identification of modulators of STAT3
signaling could have therapeutic implications in various
pathologies including cancer. Our work has identified RIP4
as a novel regulator of STAT3 signaling in lung tumors.
Reduced RIP4 expression in human lung cancer cells
enhanced STAT3 signaling whereas the opposite was true
upon overexpression of RIP4, in a kinase activity-independent
manner. Analysis of KP tumors with Rip4 knockdown showed
increased nuclear Stat3 levels by IHC and an enrichment of
Jak-Stat signaling by microarray. These tumors progressed to
a poorly differentiated state as indicated by the differentiation
markers Ttf1 and Hmga2. In human lung AC,RIP4 levels were
significantly reduced in poorly differentiated tumors, which is
consistent with a recent finding reporting reduced RIP4 levels
in poorly differentiated human tongue squamous cell
carcinoma.40 Thus, the effect of RIP4 on tumor differentiation
might not be restricted to lung AC.
A novel tumor suppressive role for Stat3 in Kras-driven lung
AC was recently identified. Tumor cell-specific Stat3 knockout
in KrasG12D tumors resulted in increased tumorigenesis.14
Mechanistic analysis showed that cytoplasmic Stat3 retained
NF-κB in an inactive state. Despite increased tumorigenesis,
Stat3-deficient tumors did not progress to a more invasive or
metastatic state. Though inactive, cytoplasmic Stat3 might be
tumor suppressive, the contribution of activated nuclear Stat3
needs to be further evaluated. A contrasting study reported
that activated Stat3 promoted NF-κB nuclear retention and
hence tumorigenesis.41 Since RIP4 is known to activate
NF-κB in a kinase activity-dependent manner, we examined
the activation of NF-κB in tumors with Rip4 knockdown. Our
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Figure 5 Model of the effect of RIP4 in tumor differentiation. RIP4 inhibits STAT3
activity, and maintains lung cancer cells in a well-differentiated epithelial state marked
by high levels of TTF1 and no HMGA2. However, upon RIP4 knockdown, sustained
signaling through STAT3 promotes the expression of ECM remodeling genes. This
results in cancer cell dedifferentiation marked by expression of HMGA2 and low levels
of TTF1
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results suggest that the contribution of Rip4 to lung tumor
differentiation is NF-κB independent.
The ability of cancer cells to extravasate and colonize
distant organs is a crucial step in metastasis. Tail vein injection
of cancer cells overexpressing RIP4 or RIP4KD significantly
reduced the number of colonies found in the lung suggesting
that RIP4 reduces the metastatic potential of the cells in a
kinase-independent manner. This effect of RIP4 on invasive-
ness was rescued by a concomitant overexpression of Stat3.
Overexpression of RIP4 or RIP4KD significantly reduced the
migration of cells through matrigel and collagen, an important
constituent of the basement membrane. Conversely, stimula-
tion with IL6 potentiated the migration of cells with RIP4
knockdown suggesting that sustained STAT3 signaling
promotes the metastatic potential of these cancer cells.
LOX, a secreted amine oxidase involved in collagen
crosslinking, has been associated with invasion of cancer
cells at the primary site42,43 and also formation of pre-
metastatic niches at distant sites.44 In Kras(G12D)-mediated
oncogenesis, Lox has been reported to promote lung AC
progression and invasion through excess collagen deposition
and β1 integrin signaling.45 Inhibition of Lox enzymatic activity
alleviates this effect. Microarray analysis of tumors with Rip4
knockdown showed an increased expression of various
extracellular remodeling enzymes including Lox, Loxl1 and
Loxl4. Picrosirius red staining of these tumors demonstrated
an increase in collagen deposition. A recent study on tumor
initiating cells showed that pSerSTAT3 promoted collagen17
expression resulting in enhanced tumor initiating capacity of
these cells.46 Our in vitro analyses showed that STAT3
pathway activation promoted the expression of LOX, which
was reverted upon overexpression of RIP4, WT or KD.
Altogether with the analysis of human lung AC samples that
showed that patients with high RIP4 and low LOX levels had
the best prognosis, these results suggest that ECM remodel-
ing participates in the progression of lung AC to a poorly
differentiated malignant state observed upon loss of RIP4.
Mutant KRAS-driven cancers are challenging to treat due to
the lack of efficient targeted therapy. Our study highlights the
importance of sustained Stat3 signaling, and its regulation by
Rip4, in an autochthonous model of oncogenic Kras-driven
lung cancer. STAT3 signaling blockade using JAK inhibitors
could prove to be therapeutically useful in late-stage lung AC.
Besides differentiation of lung and tongue cancer, RIP4 has
also been involved in developmental differentiation disorders
such as bartsocas papas syndrome, features of which are
recapitulated inRip4 knockout mice. Future studies evaluating
the role of STAT3 signaling in malignancies or in such
developmental disorders could prove to be therapeutically
useful.
Materials and Methods
Cell culture and counting. NCI-H2009, human embryonic kidney (HEK)
293Tand mouse KP (M8) cells were cultured in RPMI supplemented with 10% FBS
and 1% penicillin–streptomycin (5000 U/ml). For serum-deprived conditions, cells
were cultured in RPMI without FBS. When cells were 80–90% confluent, they were
split using 2 ml of 0.05% trypsin and reseeded onto fresh plates. For doxycycline-
inducible system, cells were cultured in RPMI supplemented with FBS, penicillin–
streptomycin and 2 μg/ml of doxycycline hyclate (D9891-1G; Sigma-Aldrich,
Schnelldorf, Germany). For IL6 (CHI-HR-20006; Chimerigen Laboratories,
Adipogen, Epalinges, Switzerland) treatment, stock concentration was prepared
at 100 μg/ml and later diluted in supplemented RPMI to 50 ng/ml final concentration
used for stimulation. For leptomycin B (L2913-.5UG; Sigma-Aldrich) treatment, cells
were cultured in RPMI with 10 ng/ml leptomycin B. To measure the number of live
cells, 10 μl of cells were mixed with 10 μl trypan blue and counted using an
automated cell counter (Countess, Life Technologies, Zug, Switzerland). LOX
inhibitor 3-Aminopropionitrile fumarate salt (BAPN) was purchased from Sigma-
Aldrich (A3134-5G).
Real-time polymerase chain reaction. RNA was extracted from cells and
tumors using trizol (15596018, ThermoFisher Scientific, Reinach, Switzerland). One
microgram of RNA was used for reverse transcription using High capacity cDNA
reverse transcription kit (4368814, ThermoFisher Scientific). Real-time PCR was
done using Taqman universal PCR master mix (4324018, ThermoFisher Scientific)
and Taqman probes for the studied genes (ThermoFisher Scientific). Levels of
mRNA were normalized to GAPDH and Rpl30 for human and mouse cells,
respectively.
Protein extraction and western blot. Cell proteins were extracted using
RIPA buffer (20 mM Tris pH8.0, 50 mM NaCl, 0.5% sodium deoxycholate, 0.1%
SDS, 1 mM Sodium orthovanadate, protein inhibitor cocktail (Sigma-Aldrich)). Cell
lysates were treated with benzonase (70746, Merck Millipore, Schaffhausen,
Switzerland). To obtain nuclear and cytoplasmic fractions, cells were lysed in
EMSA-A buffer (20 mM Hepes pH 7.6, 20% glycerol, 10 mM NaCl, 1.5 mM MgCl2,
0.2 mM EDTA, 1 mM DTT, 0.1% NP-40, 1 mM sodium orthovanadate, protein
inhibitor cocktail) and centrifuged. The supernatant was collected as the cytoplasmic
fraction and the pellet was washed thrice with EMSA-A. The nuclear proteins were
extracted by resuspending the pellet in EMSA-B (similar to EMSA-A with an
exception of 500 mM NaCl). All extracted proteins were mixed with 3 × sample
loading buffer (187.5 mM Tris-HCl, 0.03% Phenol Red, 6% SDS, 30% glycerol,
30 mM DTT). Samples were then run through 8% or 10% polyacrylamide gels for
35 min at 200 V. The proteins were then transferred to PVDF membranes. The
membranes were blocked with 5% milk in PBS-tween followed by blotting with
primary antibody. RIP4 (1:50, H00054101-M01 Abnova, LuBioScience, Luzern,
Switzerland), STAT3 (1:1000, 4904 Cell Signaling, BioConcept AG, Allschwil,
Switzerland), PARP (1:1000, 9532 Cell Signaling), β-tubulin (1:1000, sc-9104 Santa
Cruz Technology, LabForce AG, Muttenz, Switzerland), phospho-tyrosine STAT3
(1:1000, 9145 Cell Signaling), phospho-serine STAT3 (1:1000, 9134 Cell Signaling),
p65 (1:1000, sc-372 Santa Cruz Technology), p100/p52 (1:1000, 05-361 Merck
Millipore) and NEMO (1:1000, sc-8330 Santa Cruz Technology) antibodies
were used.
Histology. Tumors and lungs were fixed in 1 : 10 volume ratio of 3.7%
formaldehyde solution (A0823.0500, Axon Lab, Le Mont-sur-Lausanne, Switzerland)
for at least 24 h and then embedded in paraffin. Sections of 4 μm thickness were
cut using a microtome and mounted on polarized glass slides (Super Frost Plus,
Thermo Scientific). The sections were stained with H&E for morphologic
assessment.
Histopathology. Histopathologic analysis of tumors was performed in a
blinded fashion by a board certified veterinary pathologist. The parameters
considered to evaluate morphologic differentiation of AC were: overall architecture
of the mass and cells arrangement patterns, cells shape, anisocytosis,
anisokaryosis, number of nuclei/presence of multinucleated giant neoplastic cells,
cell and nuclear polarity.
Immunohistochemistry and immunofluorescence. Antigen retrieval
for IHC was done on tissue embedded polarized glass slides with 10 mM sodium-
citrate and blocked with 0.3% hydrogen peroxide (Sigma-Aldrich). Tissue sections
were then blocked with goat serum and stained with primary antibody. Hmga2
(1 : 400, 8179 Cell Signaling), Ttf1 (1 : 200, 5883-1 Epitomics, Burlingame, CA,
USA), Stat3 (1 : 800), phospho-tyrosine Stat3 (1 : 400), phospho-serine Stat3
(1 : 400), p65 (1 : 200, sc-372 Santa Cruz Technology), phospho-histone H3
(1 : 200, 9701 Cell Signaling) and cleaved caspase-3 (1 : 200, 9664 Cell Signaling)
antibodies were used. Biotinylated secondary antibody was used followed by
treatment with avidin bound peroxidase enzyme (ABC kit, Vectastain, Reactolab SA,
Servion, Switzerland). DAB and hydrogen peroxide were used as substrate for the
peroxidase enzyme. Harris haematoxylin was used as counter stain. Cells were
fixed using 10% formaldehyde for IF. Stat3 (1 : 800) antibody was used for staining.
The nucleus was stained using Hoechst 33342. Quantification of IF was performed
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using ImageJ. Clipping mask for the nucleus was created using the signal from
Hoechst 33342. This mask was then applied on the corresponding Stat3 image to
quantify the nuclear Stat3 intensity. A clipping mask for the whole cell was created
using Stat3 signal. Subtracting the nuclear mask from the whole cell mask created a
cytoplasmic mask. This was then applied on the Stat3 image to quantify the
cytoplasmic Stat3 intensity.
Tail vein injections. Transduced M8 Cells were treated with doxycycline for
2 days before injection to overexpress RIP4 or RIP4KD. C57BL/6 mice receiving
RIP4 or RIP4KD-overexpressing cells were given doxycycline in their food starting
from 1day before injection until the end of the experiment. Control mice were
injected with cells (not treated with doxycycline) and the mice did not receive
doxycycline. A total of 2 × 105 cells were injected through the tail vein. Lungs were
extracted 31 days after injection and embedded in paraffin.
Autochthonous mouse model. Transduction units (3500) of lentivirus
carrying plasmid with Cre recombinase was delivered through the trachea of
13-week old KrasLSLG12D/wt; p53fl/fl mice. Littermates were infected with virus
carrying shp53 or shRip4. Tumor growth was monitored using μCT. Mice were
sacrificed 18.5 weeks after tumor initiation. Lungs and tumors were either used for
mRNA extraction or embedded in paraffin. All mouse experiments were performed
with the permission of the Veterinary Authority of the Canton de Vaud, Switzerland
(license number VD2391).
Plasmid and viral production. Flag-tagged human RIP4 and RIP4KD
constructs in pCR3.1 plasmids were described previously.47 To transduce H2009
cells, inducible human RIP4 and RIP4KD constructs were cloned into pCW22
lentiviral vector using the forward oligo 5′-CTCGTT AACGCCACCATGGATTACAA
AGACGATGACGATAAAATGGAGGGCGACGGCGGG-3′ and the reverse oligo
5′-CTCTTAATTAACTAGGTCTTGCTTCGCCG-3′. The PCR products were digested
and cloned using Hpa1 and Pac1. pLKO.1 plasmid expressing shRNA against
human RIP4 was purchased from Sigma-Aldrich. shRNA against mouse Rip4 was
designed using pSICOLIGOMAKER 1.5 program prepared by annealing the forward
oligo 5′- TGAAGCCATTTGCAGATGAATTCAAGAGATTCATCTGCAAATGGCTTCT
TTTTTC-3′ and reverse oligo 5′-TCGAGAAAAAAGAAGCCATTTGCAGATGAATC
TCTTGAATTCATCTGCAAATGGCTTCA-3′. They were cloned into U6-shRNA-Pgk-
Cre plasmid from Professor Tyler Jacks’ Laboratory (MIT, Cambridge, USA) using
XhoI and HpaI. 293 T cells were transfected using lipofectamine 2000 (Thermo-
Fisher Scientific) with the necessary lentiviral vector mentioned earlier and lentiviral
packaging vectors pMD2G (VSV-G protein) and pCMVR8.74 (obtained from
Professor Didier Trono’s Laboratory, EPFL, Lausanne, Switzerland). After 6–8 h
transfection, the medium was replaced with FBS-supplemented RPMI. The
conditioned medium-containing virus was harvested 36 and 60 h post transfection.
To infect cell lines, conditioned medium was added to the cells for 48 h and then
cells were selected using puromycin or blasticidin. To infect mice, the virus was
concentrated by ultra-centrifugation (50 000 × g, 120 min, 16 °C). The pellet was
then solubilized in PBS. The TRE-mouseStat3-HA plasmid was from a previously
described library.48
CRISPR/Cas9 gene editing. RIP4 knockout H2009 cells were generated
using CRISPR/Cas9 gene editing. Lentiviral plasmid pL-CRISPR.EFS.tRFP was
used to transduce H2009 cells to develop control (without sgRNA) or RIP4 knockout
cells (with sgRNA against RIP4). The following sgRNAs were used:
sgRNA1 forward: 5′ CACCGCGTGAACTCGCCCGCGTCGA 3′
sgRNA1 Reverse: 5′ AAACTCGACGCGGGCGAGTTCACGC 3′
sgRNA2 forward: 5′ CACCGCAGGCTGGGCGAGCACTTGA 3′
sgRNA2 reverse: 5′ AAACTCAAGTGCTCGCCCAGCCTGC 3′
The oligonucleotides were annealed and ligated into the plasmid, which was
digested using Bsmb I restriction enzyme. Lentiviral vectors were produced using
these plasmids. Following transduction, H2009 cells were amplified and sorted for
RFP. RFP-positive cells were amplified and used for experimentation.
Matrigel-collagen invasion assay. Collagen type I (354236, Corning,
Amsterdam, Netherlands) solution was prepared in PBS/NaOH with a final NaOH
concentration of 20 mM and Collagen concentration of 3 mg/ml. In total, 75 μl
growth factor-reduced Matrigel (356231, Corning), 100 μl non-supplemented
DMEM, 200 μl collagen solution and 125 μl cell suspension containing 62 500
cells were mixed using vortex. A volume of 150 μl gel-cell mixture was added to
Millicell-PCF 8.0 μm insert of 12 mm diameter and put into 24 well plates. A volume
of 300 μl supplemented medium was added to the bottom and 650 μl was added to
the top of the chamber. After incubation for 16 h at 37 °C, the chambers were
removed and the medium was aspirated. The membrane at the bottom of the
transwell was washed with PBS and fixed with cold methanol. The cells were
stained with Hoechst 33342 and counted under the microscope.
Bioinformatics. All statistical analyses were performed using the free high-
level interpreted statistical language R (version 3.0.1) and various Bioconductor
packages (http://www.Bioconductor.org).
(A) Exploration of public data sets:
(1) A collection of five public lung cancer transcriptome resources has been used to
investigate RIP4 and LOX expression levels and their impact on patient survival.
Four data sets were collected from the multi-site study described by Shedden
et al.,49 and the fifth data set is described in the study by Zhu et al.50 The five
resources were combined as follows. Raw expression data from Affymetrix
Human Genome U133A Array were downloaded from Gene Expression
Omnibus (GEO: http://www.ncbi.nlm.nih.gov/geo/). Each data set was back-
ground subtracted and normalized using the robust multi-array average (RMA)
method from affy package (version 1.44.0). The batch effect correction method
ComBat from sva package (version 3.12.0) was applied to combine the data sets.
Patients were divided into high and low risk groups on the basis of RIP4 and LOX
expression; continuous expression variable was dichotomized using the median.
A survival analysis was performed with the Kaplan–Meier method to compute
survival curve, hazard-ratio and confidence interval. Differences between curves
were assessed using the log rank test (Mantel–Cox). Distributions of expression
values have been examined for different grade of tumor differentiation with the
non-parametric Kruskal–Wallis rank-sum test. The P-values issued from the test
are reported on the figures. All tests were two-sided and P-values below 0.05
were considered statistically significant.
(2) TCGA's Lung Adenocarcinoma (LUAD) was retrieved from The Cancer Genome
Atlas (TCGA project: http://cancergenome.nih.gov/). Samples with both clinical
information and mRNA (RNASEQV2) data were selected and the data was
downloaded using the RTCGA package.51 Normalized RSEM gene counts as
provided by TCGA were taken. As a filtering step, only genes with counts per
million41 in at least 50 samples are kept for further analysis and then counts are
converted to log-counts per million using voom function from limma package.52
Out of 480 samples, we had survival information for 448 samples; mutational
information was available only in 198 samples. A total of 73 samples with a
mutation in KRAS (G12 or Q61), 99 samples with a mutation in TP53 (nonsense,
missense, frame shift mutations, in frame deletion) and survival data were used
for survival analysis. Differences in expression levels between mutant samples
groups were assessed by Kruskal–Wallis rank-sum test.
(B) Microarray analysis: RNA was prepared and hybridized to Affymetrix
GeneChIP 2.0 STarrays (Affymetrix, Santa Clara, CA, GPL16570) by the Lausanne
Genomic Technologies Facility, Center for Integrative Genomics (University of
Lausanne, Switzerland). Data were normalized using the RMA algorithm from the
xps package (version 1.26.1) and analyzed using the limma package (version
3.22.7). Differential expression of genes between controls and Rip4 KO mice has
been assessed with the standard procedure described in the limma package using
the eBayes method. The GSEA has been performed with the roast method of the
limma package, a self-contained rotation gene set test proposed by Wu et al.53
Gene sets were collected from MSigDB (version 4) with homolog mapping from
human to mouse genes. A false discovery ratio threshold of 0.05 was applied for
calling a gene set as statistically significantly associated with the observed gene
expression difference between the conditions.
Transfection. H2009 cells were grown to 60% confluence in a 10 cm plate.
Control siRNA, Rip4 siRNA and KRAS siRNA were purchased from ThermoFisher
Scientific. siRNAs were diluted to a final concentration of 10 nM. Lipofectamine
RNAiMAX (ThermoFisher Scientific) was mixed with siRNA in non-supplemented
medium and added to cells. After 8 h, the medium was replaced with
FBS-supplemented RPMI medium.
Accession numbers. The accession number for the Microarray Data is GEO:
GSE81154.
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Statistics. Cell culture experiments were repeated at least in biological triplicates
to accommodate technical variations. If the positive and negative control conditions
did not meet the experimental criteria, the samples were excluded from analysis.
For mouse experiments, initial analysis of groups of five or more mice for each
condition suggested a requirement and sufficiency of three mice per group unless
an abnormal variation within the cohort was observed. During the course of
experimentation, the mice were regularly scanned for tumors using μCT. If the
mouse was found to have deteriorated health (as suggested by the veterinarian),
abnormal for the tumor burden and age, the mouse was excluded from analysis. All
μCT scans were performed blind. All animals in a particular experiment were age
matched. However, the selection of animals in each group was entirely random. The
statistical methods applied are mentioned in the figure legends. For samples
obtained from mouse experiments, Mann–Whitney test was appropriate for the
sample size and analysis.
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